Evidence map›Paper›PMID 31736256›Full record

ArticleCancer medicine2020

Are population-based patient-reported outcomes associated with overall survival in patients with advanced pancreatic cancer?

Wei Fang Dai, Jaclyn Beca, Helen Guo, Wanrudee Isaranawatchai, Deborah Schwartz, Rohini Naipaul, Jessica Arias, Yao Qiao, Scott Gavura, Ruby Redmond-Misner and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Characteristics of patients diagnosed with pancreatic cancer who access palliative care: An observational study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2023
    Observational
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Wei Fang DaiCancer Care Ontario, Toronto, ON, Canada.ORCID 0000-0002-1416-1070
Jaclyn BecaCancer Care Ontario, Toronto, ON, Canada.
Helen GuoCancer Care Ontario, Toronto, ON, Canada.
Wanrudee IsaranawatchaiCancer Care Ontario, Toronto, ON, Canada.
Deborah SchwartzCancer Care Ontario, Toronto, ON, Canada.
Rohini NaipaulCancer Care Ontario, Toronto, ON, Canada.
Jessica AriasCancer Care Ontario, Toronto, ON, Canada.
Yao QiaoCancer Care Ontario, Toronto, ON, Canada.
Scott GavuraCancer Care Ontario, Toronto, ON, Canada.
Ruby Redmond-MisnerCancer Care Ontario, Toronto, ON, Canada.
Zahra IsmailCancer Care Ontario, Toronto, ON, Canada.
Lisa BarberaCancer Care Ontario, Toronto, ON, Canada.ORCID 0000-0002-8302-4117
Kelvin ChanCancer Care Ontario, Toronto, ON, Canada.ORCID 0000-0002-2501-3057
Cancer Care Ontario · CASt. Michael's Hospital · CASunnybrook Health Science Centre · CAUniversity of Calgary · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdvanced pancreatic cancer (APC) patients often have substantial symptom burden. In Ontario, patients routinely complete the Edmonton Symptom Assessment Scale (ESAS), which screens for nine symptoms (scale: 0-10), in cancer clinics. We explored the association between baseline patient-reported outcomes, via ESAS, and overall survival (OS).

methodsAdvanced pancreatic cancer patients with ESAS records prior to receiving publicly funded drugs from November 2008 to March 2016 were retrospectively identified from Cancer Care Ontario's administrative databases. We examined three composite ESAS scores: total symptom distress score (TSDS: 9 symptoms), physical symptom score (PHS: 6/9 symptoms), and psychological symptom score (PSS: 2/9 symptoms); Composite scores greater than defined thresholds (TSDS ≥36, PHS ≥24, PSS ≥8) were considered as high symptom burden. Crude OS was assessed using Kaplan-Meier method. Hazard ratios (HRs) were assessed using multivariable Cox models. Analysis was repeated in a sub-cohort with Eastern Cooperative Oncology Group (ECOG) status and metastasis.

resultsWe identified 2199 APC patients (mean age 64 years, 55% male) with ESAS records prior to receiving chemotherapy. Crude median survival was 4.5 and 7.3 months for high and low TSDS, respectively. High TSDS was associated with lower OS (HR = 1.47, 95% CI: 1.33, 1.63). In the sub-cohort (n = 393) with ECOG status and metastasis, high TSDS was also associated with lower OS (HR = 1.34, 95% CI: 1.04, 1.73). Similar trends were observed for PHS and PSS.

conclusionsHigher burden of patient-reported outcome was associated with reduced OS among APC patients. The effect was prominent after adjusting for ECOG status.

Indexed as

Patient Reported Outcome MeasuresSeverity of Illness IndexAdministrative Claims, HealthcareAgedDatabases, FactualFemaleHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingOntarioPancreatic NeoplasmsPrognosisRetrospective StudiesSymptom Assessmentadvanced pancreatic cancerpatient-reported outcome measuressurvival

Identifiers

PMID31736256
PMCPMC6943146
OpenAlexW2984019862

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.